» Articles » PMID: 3741725

Investigation of Patients with Abnormal Response to Warfarin

Overview
Specialty Pharmacology
Date 1986 Jul 1
PMID 3741725
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

In 55 patients in whom warfarin control had been satisfactory for at least 4 months, warfarin dose, plasma warfarin concentration and plasma clearance were measured. The mean dose to maintain the BCR (INR) between 2.3 and 3.3 was 5.1 +/- 2 mg day-1 (range 1.5-10 mg). Plasma warfarin concentrations and warfarin clearance were log-normally distributed with 95% confidence limits between 0.8 and 2.4 mg l-1 and 2.5 and 8.71 day-1 respectively. These confidence limits were used to construct algorithms which correctly predicted the cause of abnormal warfarin sensitivity in two patients and resistance in two further patients. These algorithms should help to identify the cause of abnormal warfarin responsiveness in the clinical setting.

Citing Articles

Anticoagulant therapy in special circumstances.

DeLoughery T Curr Cardiol Rep. 2000; 2(1):74-9.

PMID: 10980876 DOI: 10.1007/s11886-000-0029-y.


Clinical utilization of the international normalized ratio (INR).

RILEY R, Rowe D, Fisher L J Clin Lab Anal. 2000; 14(3):101-14.

PMID: 10797608 PMC: 6807747. DOI: 10.1002/(sici)1098-2825(2000)14:3<101::aid-jcla4>3.0.co;2-a.


Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

Vadher B, PATTERSON D, Leaning M Br J Clin Pharmacol. 1999; 48(1):63-70.

PMID: 10383562 PMC: 2014877. DOI: 10.1046/j.1365-2125.1999.00967.x.


Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism.

Routledge P, Shetty H, White J, Collins P Br J Clin Pharmacol. 1998; 46(4):343-6.

PMID: 9803981 PMC: 1874165. DOI: 10.1046/j.1365-2125.1998.t01-1-00796.x.


Clinically important drug interactions with anticoagulants. An update.

Harder S, Thurmann P Clin Pharmacokinet. 1996; 30(6):416-44.

PMID: 8792056 DOI: 10.2165/00003088-199630060-00002.


References
1.
Robinson D, Benjamin D, McCormack J . Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther. 1971; 12(3):491-5. DOI: 10.1002/cpt1971123491. View

2.
ANDREASEN P, Vesell E . Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin Pharmacol Ther. 1974; 16(6):1059-65. DOI: 10.1002/cpt19741661059. View

3.
Yacobi A, Udall J, Levy G . Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther. 1976; 19(5 Pt 1):552-8. DOI: 10.1002/cpt1976195part1552. View

4.
Bjornsson T, Blaschke T, Meffin P . High-pressure liquid chromatographic analysis of drugs in biological fluids I. Warfarin. J Pharm Sci. 1977; 66(1):142-4. DOI: 10.1002/jps.2600660144. View

5.
OReilly R, AGGELER P, HOAG M, Leong L, KROPATKIN M . HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED. N Engl J Med. 1964; 271:809-15. DOI: 10.1056/NEJM196410152711602. View